Skip to main content

Sionna Therapeutics, Inc. (SION) Stock Analysis

Range Bound setup

SellModerate Confidence

Healthcare · Biotechnology

Sell if holding. Engine safety override at $41.11: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.3/10. Specifically: High short interest: 15%; Elevated put/call ratio: 4.00; Below-average business quality.

Sionna Therapeutics is a clinical-stage CF biopharma developing NBD1 stabilizers for cystic fibrosis: SION-719 in Phase 2a as add-on to standard of care (topline data expected mid-2026) and SION-451 in Phase 1 dual-combination trials. The company has no approved products and is... Read more

$41.11+14.4% A.UpsideScore 4.3/10#140 of 157 Biotechnology
QualityF-score2 / 9FCF yield-2.58%
Stop $36.49Target $44.89(analyst − 13%)A.R:R 1.0:1
Analyst target$51.60+25.5%10 analysts
$44.89our TP
$41.11price
$51.60mean
$23
$63

Sell if holding. Engine safety override at $41.11: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.3/10. Specifically: High short interest: 15%; Elevated put/call ratio: 4.00; Below-average business quality. Chart setup: RSI 49 mid-range, Bollinger mid-band. Score 4.3/10, moderate confidence.

Passes 6/8 gates (clean insider activity, no SEC red flags, news boost analyst 0.80, earnings proximity 83d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: aggressive.

Val6.0Qual1.2Grw5.0Mom2.5Sent7.6Ins3.0Peer4.9Tech6.0Risk1.14.3OVERALL

Recent Developments — Sionna Therapeutics, Inc.

Latest news

Generated 2026-05-20T21:06:21Z.

Thesis

Rewards
Recent Analyst detected in news
Risks
Concentration risk — Pipeline: NBD1 stabilizers SION-719 and SION-451
Quality below floor (1.2 < 4.0)

Key Metrics

P/E (TTM)—
P/E (Fwd)-14.0
Mkt Cap$1.8B
EV/EBITDA-15.9
Profit Mgn0.0%
ROE-26.7%
Rev Growth—
Beta—
DividendNone
Rating analysts16

Quality Signals

Piotroski F2/9

Options Flow

P/C4.00bearish
IV100%elevated
Max Pain$30-27.0% vs spot

Concentration Risks(10-K Item 1A)

  • HIGHpipelineNBD1 stabilizers SION-719 and SION-451
    10-K Item 1A: 'We are substantially dependent on the success of at least one of our NBD1 stabilizer product candidates, SION-719 and SION-451'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

3 floor-breakers

Volatile — 8.0% daily ATR makes tight stops impractical. Position-size conservatively.static

Volatility
0.0
Put Call
0.0
Implied Vol
0.0
Days To Cover
0.8
Short Interest
2.0
Debt Equity
2.1
Max Pain Risk
3.0
High short interest justified: 15%Elevated put/call: 4.00High IV: 100%Above max pain $30Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)

Quality below the gate floor. Component breakdown shows what dragged the score down.static

Roe
0.0
Roa
0.0
Gross Margin
0.0
Operating Margin
0.0
Net Margin
0.0
Fcf Quality
0.0
Piotroski F
2.2
Moat
3.2
Current Ratio
5.0
Cash-burning (FCF negative)No competitive moatWeak Piotroski F-Score: 2/9Quality concerns

Momentum below the gate floor. Component breakdown shows what dragged the score down.static

Macd
0.0
Obv
1.0
Volume
2.1
Ma Position
4.0
Rsi
5.5
Volume distribution (falling OBV)Above 200-day MA
GatesMomentum 2.5<4.5A.R:R 1.0 < 1.5@spotInsider activity: OKNo SEC red flagsNEWS BOOST ANALYST 0.80EARNINGS PROXIMITY 83d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARRange BoundSuitability: Aggressive
RSI
49 · Neutral
↓ 20D MA↓ 50D MA↑ 200D MAGOLDEN CROSSSupport $35.10Resistance $48.45

Price Targets

$36
$45
A.Upside+9.2%
A.R:R1.0:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! Quality below floor (1.2 < 4.0)
! Momentum score 2.5/10 — below 4.5 minimum
! Reward/Risk 1.0:1 at current price — below 1.5:1 minimum

Earnings

B
B
M
M
2/4 beats
Next Earnings2026-08-10 (83d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is SION stock a buy right now?

Sell if holding. Engine safety override at $41.11: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.3/10. Specifically: High short interest: 15%; Elevated put/call ratio: 4.00; Below-average business quality. Chart setup: RSI 49 mid-range, Bollinger mid-band. Prior stop was $36.49. Score 4.3/10, moderate confidence.

What is the SION stock price target?

Take-profit target: $44.89 (+14.4% upside). Prior stop was $36.49. Stop-loss: $36.49.

What are the risks of investing in SION?

Concentration risk — Pipeline: NBD1 stabilizers SION-719 and SION-451; Quality below floor (1.2 < 4.0).

Is SION overvalued or undervalued?

Sionna Therapeutics, Inc. trades at a P/E of N/A (forward -14.0). TrendMatrix value score: 6.0/10. Verdict: Sell.

What do analysts say about SION?

16 analysts cover SION with a consensus score of 4.2/5. Average price target: $52.

What does Sionna Therapeutics, Inc. do?Sionna Therapeutics is a clinical-stage CF biopharma developing NBD1 stabilizers for cystic fibrosis: SION-719 in Phase...

Sionna Therapeutics is a clinical-stage CF biopharma developing NBD1 stabilizers for cystic fibrosis: SION-719 in Phase 2a as add-on to standard of care (topline data expected mid-2026) and SION-451 in Phase 1 dual-combination trials. The company has no approved products and is entirely dependent on the success of its NBD1 stabilizer pipeline.

Related stocks: AUPH (Aurinia Pharmaceuticals Inc) · ADMA (ADMA Biologics Inc) · HALO (Halozyme Therapeutics, Inc.) · KRYS (Krystal Biotech, Inc.) · INVA (Innoviva, Inc.)